IMSC: Identification of Phospholipid Species Implicated in Dementia by Untargeted LC/HRMS and Data Dependent MS/MS

Importance of the Topic

This study addresses the critical need for precise identification of molecular phospholipid species in human plasma to support Alzheimer’s disease research and biomarker discovery. Detailed fatty acid composition helps differentiate isomeric lipids that may serve as early indicators of cognitive impairment.

Objectives and Overview

The primary goal is to unambiguously determine the fatty acid constituents of lyso-PC 18:2, PC 36:6, 38:0, 38:6, 40:1, 40:2, 40:6 and the ether form 40:6e in human plasma. The study compares untargeted label-free workflows in Proteome Discoverer 2.2 with targeted SRM assays, and employs LipidSearch 4.1 for automated lipid identification and confirmation.

Methodology and Instrumentation

Sample Preparation:

• Human plasma aliquots (30 µL) from control, mild cognitive impairment and Alzheimer’s patients.
• Bligh & Dyer extraction; reconstitution in 50:50 IPA/methanol.

LC-HRAM MS Conditions:

• Thermo Scientific™ Orbitrap Fusion™ Lumos™ Tribrid mass spectrometer.
• Thermo Scientific™ Dionex™ UltiMate™ 3000 UHPLC with C30 Acclaim™ column (2.1 × 150 mm, 3 µm).
• Data-dependent HCD MS2 at 15K resolution; supplemental CID MS2 when m/z 184.0733 detected.

Data Processing and Lipid Identification:

• Proteome Discoverer 2.2 with Minora Feature Detector for untargeted feature detection, retention time alignment and consensus quantification.
• LipidSearch 4.1 parameters: precursor/product tolerances 5 ppm; adducts [M+H]+, [M+Na]+, [M+HCO2]−; database search of phospholipids, glycerolipids, sphingolipids and neutral lipids.

Main Results and Discussion

Identification Outcomes:

• Detected and confirmed 23 lyso-PC and 67 PC molecular species by matching precursor and fragment ions in both positive and negative mode MS2.
• Resolved PC 38:6 into three isomers (18:2_20:4, 18:1_20:5, 16:0_22:6) based on characteristic neutral losses and fatty acid anions; relative abundances established.
• Validated panel lipids previously linked to dementia and corrected misassignments from low-resolution SRM (e.g. PC 38:0 vs PC 40:7e).

Discussion:
This high-resolution approach provides unambiguous fatty acid assignment in complex plasma matrices, overcoming limitations of infusion SRM and spectral counting. The combined HCD/CID strategy enhances confidence in headgroup and acyl chain characterization.

Benefits and Practical Applications

• Comprehensive untargeted lipid profiling to support biomarker discovery and mechanistic studies in neurodegeneration.
• Automated workflows in Proteome Discoverer and LipidSearch streamline data analysis for large cohorts.
• High mass accuracy and MS2 specificity reduce false positives and improve reproducibility in clinical research.

Future Trends and Applications

Advances may include expansion of untargeted workflows to additional lipid classes, integration with quantitative label-free and isotopic methods, development of larger spectral libraries, and application in longitudinal clinical studies for early disease detection.

Conclusion

This work demonstrates that Orbitrap-based LC-MS/MS combined with advanced software pipelines enables accurate and high-throughput identification of phospholipid species in human plasma, providing a robust platform for Alzheimer’s biomarker research.

References

• Mapstone M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nature Medicine 2014;20(4):415–418.
• Kiyonami R. et al. Large-scale lipid profiling of a human serum lipidome using a high-resolution, accurate-mass LC/MS/MS approach. Thermo Fisher Scientific Application Note 647, 2016.
• Kiyonami R. et al. Increased throughput and confidence for lipidomics profiling using comprehensive HCD MS2 and CID MS3 on a Tribrid Orbitrap mass spectrometer. Thermo Fisher Scientific Application Note 648, 2016.